Drug Trial Radar · NCT06943404
BXCL501 After Stress to Increase Recovery Success
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Feb 23, 2026
Primary completion
Sep 29, 2027
Study completion Sep 29, 2027
Sponsor
- Lead sponsor
- University of North Carolina, Chapel HillAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- United States Department of Defense; Mclean Hospital; Washington University School of Medicine; University of Florida; Rhode Island Hospital; Vanderbilt University School of Medicine; Walter Reed Army Institute of Research (WRAIR); Lakeland Regional Health Systems, Inc.
- First posted
- Apr 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will examine the safety and efficacy of BXCL501 to reduce ASR symptoms and behavioral changes among patients presenting to the Emergency Department (ED) after Motor Vehicle Collision (MVC). Specifically, the investigators will perform the BXCL501 (BASIS) Trial, a double-blind placebo-controlled Randomized Controlled Trial (RCT) to determine if BXCL501 (dexmedetomidine hydrochloride sublingual film) initiated in the ED in the hours after MVC to high risk individuals, treats/reduces ASR/ASD symptoms (primary outcome), improves neurocognitive function, and prevents/reduces posttraumatic stress (PTS) symptoms (secondary outcomes) long term. 100 participants will be randomized, receive study drug in ED and be discharged with a 2-week drug supply. Prior to initial dose of study drug administration, and during the hours, days, and weeks after participants will receive serial longitudinal assessments of psychological and somatic symptoms, neurocognitive function, and adverse events.
Conditions
- Acute Stress Reaction
- Acute Stress Disorder
- Post-traumatic Stress Disorder
Interventions
BXCL501 (dexmedetomidine HCl)Drug
BXCL501 (dexmedetomidine HCl) taken sublingually (under the tongue) in the ED and at bedtime over 2 weeks.
PlaceboDrug
Placebo taken sublingually (under the tongue) in the ED and at bedtime over 2 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in ASD ScoreTime frame: Week 1, 3 after MVC
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Florida College of Medicine - Jacksonville
Jacksonville, Florida · Recruiting
Lakeland Regional Health
Lakeland, Florida · Recruiting
Washington University in St. Louis
St Louis, Missouri · Not yet recruiting
UVA University Hospital
Charlottesville, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.